MAPK and IL-6-mediated signaling pathways impact immature MDSCs (i-MDSCs) in the TME, which are activated by IL-6 and attracted to tumor locations where they develop into mature MDSCs and decrease tumor immunity (37). Here, IL6 is linked to neoplasm.